Supira Medical Raises $120M in Series E Financing Round for pVAD Development

Supira Medical, a clinical-stage Shifamed portfolio company, has successfully closed an oversubscribed Series E financing round, securing $120 million to advance the development of its percutaneous ventricular assist device (pVAD). The funding was led by new investors Novo Holdings and Qatar Investment Authority, alongside participation from two undisclosed strategic investors. Existing investors including Cormorant Asset Management, The Capital Partnership, 415 Capital, AMED Ventures, PA MedTech VC Fund, and Unorthodox Ventures also joined the round.

The raised capital will be utilized to expand Supira's clinical programs for high-risk percutaneous coronary intervention (HRPCI) and cardiogenic shock (CS), including the SUPPORT II U.S. Pivotal Study for HRPCI, aimed at obtaining FDA PMA approval.

The company recently completed enrollment for its U.S. SUPPORT I Early Feasibility Study, evaluating the safety and feasibility of its pVAD in HRPCI patients. pVADs play a crucial role in providing cardiovascular support during HRPCI and in treating cardiogenic shock. Supira's System, although investigational, has shown promise in benefiting HRPCI patients.

Supira Medical, Inc. is dedicated to developing next-generation pVADs for high-risk interventional patients and those experiencing cardiogenic shock. Novo Holdings, responsible for managing Novo Nordisk Foundation's assets, is a major investor in life sciences. Qatar Investment Authority, established in 2005, is among the world's largest sovereign wealth funds. Shifamed, founded by Amr Salahieh, focuses on medical innovation to improve patient outcomes. 

Learn more about the funding here.